Mativ (MATV) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
30 Jun, 2026Executive summary
SaaS/SAS segment delivered strong Q4 and 2024 growth, with broad-based volume increases and momentum expected to continue into 2025.
FAM segment faced challenges from weak industrial demand and paint protection film quality issues, but corrective actions and turnaround plans are underway, with improvements expected in H2 2025.
Q4 2024 sales rose 1.4% year-over-year to $458.6M, with organic growth of 4.3%; full-year sales from continuing operations were $1,981.1M, down 2.2% year-over-year.
Over $20 million in overhead costs were removed in 2024, with further cost reductions and operational streamlining planned.
Adjusted EBITDA for Q4 was $44.8M (down 10% year-over-year); full-year Adjusted EBITDA was $218.0M, up 2%.
Financial highlights
Consolidated net sales for Q4 were $459 million, up 4.3% organically and 1.4% as reported year-over-year.
Adjusted EBITDA from continuing operations was $44.8 million, down 10% from $50 million in the prior year, impacted by higher input and manufacturing costs.
SaaS/SAS net sales reached $291 million, up almost 13% organically and 8% as reported; adjusted EBITDA was $36 million, up nearly 8% year-over-year.
FAM net sales were $168 million, down over 7% year-over-year; adjusted EBITDA was $26 million, down more than $10 million.
Net debt at quarter/year-end was $995 million, with available liquidity of $451 million and a net leverage ratio of 4.4x.
Outlook and guidance
Q1 2025 expected to be impacted by higher inventory and input costs, with pricing actions planned to offset inflation over the year.
Full-year 2025 focus on profit growth, cash generation, margin improvement, and aggressive cost reductions.
Capital expenditures planned at $50 million, with one-time costs of $15–$20 million and a normalized tax rate of 24%.
Raw material headwinds of $10–$15 million expected in H1 2025, to be offset by targeted pricing actions.
Improvements in FAM segment expected in the second half of 2025 as turnaround activities progress.
Latest events from Mativ
- All proposals passed, including director elections and equity plan amendment, with no questions raised.MATV
AGM 20269 May 2026 - Adjusted EBITDA rose 28% to $47.5M, with margin gains and leverage reduced to 4.1x.MATV
Q1 20267 May 2026 - Record free cash flow and EBITDA gains in 2025, despite a major goodwill impairment.MATV
Q4 202510 Apr 2026 - Operational transformation and targeted investments drive growth and margin expansion.MATV
Investor presentation25 Mar 2026 - Annual meeting to vote on directors, auditor, compensation, and equity plan amendment.MATV
Proxy Filing17 Mar 2026 - Proxy covers director elections, auditor ratification, compensation, and equity plan amendment.MATV
Proxy Filing17 Mar 2026 - Adjusted EBITDA rose 13% year-over-year, with margin and cash flow improvements in Q2 2024.MATV
Q2 20242 Feb 2026 - Adjusted EBITDA up 10% on flat sales; SAS growth offsets FAM headwinds amid restructuring.MATV
Q3 202416 Jan 2026 - All proposals passed, including director election and equity plan amendment; no questions raised.MATV
AGM 202523 Dec 2025